Headquartered in Gaithersburg, Maryland, Novavax is a biotechnology firm that focuses on the invention, improvement and commercialisation of vaccines to stop infectious ailments.
Throughout his discussions with Stanley C Erck, President, Chief Government Officer & Director at Novavax, Sandhu stated the partnership between Novavax and SII is one other instance of the “strong India-US healthcare cooperation”, particularly within the manufacturing of reasonably priced and accessible vaccines and medicines.
Erck briefed the ambassador on the excessive efficacy of the COVID-19 vaccine as per trials held thus far. In January 2020, Novavax introduced the event of a coronavirus vaccine candidate. Subsequently, Novavax and India’s SII had entered right into a vaccine manufacture settlement with the Novovax vaccine anticipated to be distributed as ‘Covavax‘ in India.
On June 14, Novavax had introduced total 90.4 per cent efficacy in Section-3 trials in US and Mexico.
Sandhu famous that healthcare sectors in each international locations have been collaborating via joint analysis, sharing of technical experience and data alternate.
The Indian envoy has reached out to a lot of pharma corporations within the US. His outreach to vaccine producers/corporations within the vaccine provide chain embody Pfizer, Moderna, Johnson & Johnson, Air Merchandise, AdvaMed, Thermo Fisher, Eli Lilly, Pall Company, Antylia, Cytiva, Genentech, Ligand, and so forth.
Earlier this month, he had additionally visited Ocugen and Jubilant Pharma services.
Based in 1987, Novavax operates via growing recombinant vaccines. The corporate, via its recombinant nanoparticle vaccine know-how, produces vaccine candidates to answer each identified and newly rising ailments.
Its product pipeline focuses on a spread of infectious ailments with vaccine candidates in scientific improvement for the respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus.